Medical Xpress January 13, 2025
Tom Snee, University of Iowa

A new study from the University of Iowa finds that many drug prices actually drop after pharmaceutical company mergers, challenging the belief that mergers are the primary cause of rising drug prices in the United States. The study finds the price drops are due to cost savings achieved by merging firms that have overlapping products that treat the same medical condition.

These results, published in the Journal of Corporate Finance, did find that industry-leading firms like Eli Lilly and Pfizer that focus on novel, first-in-class drugs raised the price of overlapping drugs by 6.3% after . However, mergers involving firms that mostly produce generic and copycat drugs, such as Teva Pharmaceuticals or Activis Generics, lowered the price of overlapping drugs...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Survey / Study, Trends
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
CVS Caremark taps Omada on GLP-1 program
23andMe is potentially selling more than just genetic data. Survey info is just as much a privacy problem
InnovationRx: Trump Administration Health Agency Layoffs Threaten Biotech Innovation
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?

Share This Article